Delisting risk
OneMedNet (ONMD)
Curates de-identified imaging and patient data for life-sciences research.
$0.5750
Pre-market−0.00 (−0.33%)
At close$0.5769(+0.82%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 |
| 2 | 4 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 3 | 2 | 1 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 1 | 3 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −2 | −4 | −2 | −2 | −2 | −3 | −2 | −2 | −2 | −3 | −3 | −2 |
| −12 | −14 | 0 | −1 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 12 | 14 | 0 | 1 | 0 | 0 | 0 | −5 | −2 | 0 | 0 | 0 |
| Income before tax | −14 | −18 | −2 | −4 | −2 | −2 | −2 | 3 | −1 | −3 | −2 | −2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −14 | −18 | −2 | −4 | −2 | −2 | −2 | 3 | −1 | −3 | −2 | −2 |
| Net income | −14 | −18 | −2 | −4 | −2 | −2 | −2 | 3 | −1 | −3 | −2 | −2 |
| EPS, basic | −$0.49 | −$1.19 | −$0.09 | −$0.15 | −$0.07 | $0.00 | −$0.06 | $0.08 | −$0.02 | −$0.07 | −$0.04 | −$0.04 |
| EPS, diluted | −$0.49 | −$1.19 | −$0.09 | −$0.15 | −$0.07 | $0.00 | −$0.06 | $0.08 | −$0.02 | −$0.06 | −$0.04 | −$0.04 |
| Weighted average shares, basic | 28 | 15 | 24 | 24 | 28 | 0 | 34 | 37 | 37 | 45 | 55 | 58 |
| Weighted average shares, diluted | 28 | 15 | 24 | 24 | 28 | 0 | 34 | 38 | 38 | 45 | 55 | 58 |
| EBITDA | −14 | −18 | −2 | −4 | −2 | −2 | −2 | 3 | −1 | −3 | −2 | −2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −14 | −18 | −2 | −4 | −2 | −2 | −2 | 3 | −1 | −3 | −2 | −2 |
